Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth trims Canadian OTC brands

This article was originally published in The Tan Sheet

Executive Summary

The pharmaceutical and nutritional products firm becomes a leaner acquisition for Pfizer by divesting Anacin pain relief and other OTC brands in Canada to Paladin Labs. Montreal-based Paladin June 29 said it agreed to acquire multiple OTC products including Anacin (acetylsalicylic acid) and Anbesol (benzocaine) topical pain reliever. The firms did not disclose the terms of the deal, but market analysts said Paladin likely paid a discounted price because Wyeth was interested in divesting the brands in advance of being acquired by Pfizer for $68 billion (1"The Tan Sheet" Feb. 2, 2009). Wyeth sold the U.S. Anacin brand to Insight Pharmaceuticals in 2003. According to Paladin, which also markets Rx drugs, in 2008 the Wyeth Canadian OTC brands generated $4 million Canadian ($3.46 million U.S.)

You may also be interested in...

Coronavirus Update: US Public Confidence In COVID-19 Vaccines Declines

Confidence in the vaccine has slipped in the US, regardless of political affiliation.

Get Real: Orbital’s Chris Bunniss On Real World Evidence’s Potential For OTC Innovation

Can "real world evidence" drive consumer health innovation? HBW Insight speaks to Orbital Research’s Chris Bunniss about RWE’s potential for the OTC industry.

Chiesi Enters Poland’s OTC Market With Smart Pharma Buy

Italy's Chiesi is looking to take a slice of Poland's consumer healthcare market by acquiring infant supplements specialist Smart Pharma.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts